KROS
NASDAQ
US
Keros Therapeutics, Inc. - common stock
$12.00
▲ +$0.31
(+2.65%)
Vol 559K
7
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$620.3M
P/E
9.6
ROE
9.5%
Margin
26.1%
D/E
0.00
Beta
0.90
52W
$9–$23
Wall Street Consensus
15 analysts · Apr 20264
Strong Buy
6
Buy
5
Hold
0
Sell
0
Strong Sell
66.7%
Buy Rating
Price Chart
Similar Stocks
ALXO
ALX Oncology Holdings Inc
$61.3M
TENX
Tenax Therapeutics Inc
$76.1M
IKT
Inhibikase Therapeutics Inc
$248.6M
VYGR
Voyager Therapeutics Inc
$218.5M
RNA
Atrium Therapeutics Inc
$10.9B
ELDN
Eledon Pharmaceuticals Inc
$113.4M
CAMP
CAMP4 Therapeutics Corp
$318.0M
NERV
Minerva Neurosciences Inc
$28.1M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.64 | $-0.86 | $-0.22 |
| Sep 2025 | $-1.07 | $-0.18 | +$0.89 |
| Jun 2025 | $-1.15 | $-0.76 | +$0.39 |
| Mar 2025 | $-0.25 | $3.62 | +$3.87 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 3.0% | 3.0% | 3.0% | 3.0% | 9.5% | 9.5% |
| P/E (TTM) | 28.88 | 31.02 | 32.67 | 24.70 | 7.96 | 9.62 |
| Net Margin | -169.0% | 8.1% | 8.1% | 8.1% | 26.1% | 26.1% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 21.11 | 21.11 | 21.11 | 21.11 | 29.86 | 29.86 |
Key Ratios
ROA (TTM)
8.9%
P/S (TTM)
2.51
P/B
1.1
EPS (TTM)
$1.54
CF/Share
$-4.93
Rev Growth 3Y
-43.9%
52W High
$22.55
52W Low
$9.12
$9.12
52-Week Range
$22.55
How does KROS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
KROS valuation vs Biotechnology peers
P/E ratio
9.6
▼
49%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.5
▼
80%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.1
▼
54%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
KROS profitability vs Biotechnology peers
ROE
9.5%
▲
114%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
26.1%
▲
109%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
8.9%
▲
119%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
KROS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
29.9
▲
572%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.9
▼
8%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
KROS fundamentals radar
KROS
Peer median
Industry
KROS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
KROS vs peers: key metrics
Latest News
No related news yet